Literature DB >> 1309357

Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis.

J L Wallace1, C M Keenan, D Gale, T S Shoupe.   

Abstract

The ability of nonsteroidal anti-inflammatory drugs to exacerbate experimental colitis, and the possible contributions of the "shunting" of arachidonate via the 5-lipoxygenase pathway, were investigated using a rat model in which colitis was induced by intracolonic administration of trinitrobenzene sulfonic acid in a vehicle of 50% ethanol. Twice daily treatment with indomethacin (0.1-1 mg/kg SC) during the first week after trinitrobenzene sulfonic acid/ethanol administration resulted in dose-dependent increases in the severity of colitis and in the incidence of mortality. Mortality was not observed in vehicle-treated colitic rats or in normal rats treated with indomethacin. Similar exacerbation of colitis was observed in rats treated with naproxen (5 mg/kg). Whereas treatment with a 5-lipoxygenase inhibitor, PF-5901 (100 mg/kg PO), resulted in a significant reduction of the severity of colitis, concomitant administration of PF-5901 and indomethacin (0.5 mg/kg SC) did not inhibit the exacerbative effects of the indomethacin in this model. In separate studies, administration of indomethacin was found to significantly increase colonic myeloperoxidase activity (a measure of tissue granulocyte numbers) and suppress colonic prostaglandin E2 synthesis, while not significantly affecting colonic leukotriene B4 synthesis. The effect on myeloperoxidase activity was seen during the period 21-24 hours after trinitrobenzene sulfonic acid ethanol administration, but not during the period 45-48 hours after induction of colitis. In in vitro studies using samples of inflamed colon and in vivo studies in which colonic eicosanoid production was measured by colonic dialysis, inhibition of prostaglandin E2 synthesis was not accompanied by significant changes in leukotriene B4 synthesis. These results suggest that inhibitors of colonic prostaglandin synthesis can markedly exacerbate colitis, and that this effect is unrelated to alterations in colonic leukotriene B4 synthesis. Endogenous prostaglandins may exert anti-inflammatory effects during the acute stages of colitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309357     DOI: 10.1016/0016-5085(92)91779-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  33 in total

1.  Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease.

Authors:  Nobuki Ichikawa; Kenichiro Yamashita; Tohru Funakoshi; Shin Ichihara; Moto Fukai; Masaomi Ogura; Nozomi Kobayashi; Masaaki Zaitsu; Tadashi Yoshida; Susumu Shibasaki; Yasuyuki Koshizuka; Yusuke Tsunetoshi; Masanori Sato; Takahiro Einama; Michitaka Ozaki; Kazuo Umezawa; Tomomi Suzuki; Satoru Todo
Journal:  Inflamm Res       Date:  2015-12-18       Impact factor: 4.575

2.  Pathogenesis of NSAID colitis.

Authors:  M Guslandi
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

3.  5-Aminoisoquinolinone reduces colon injury by experimental colitis.

Authors:  Salvatore Cuzzocrea; Emanuela Mazzon; Rosanna Di Paola; Tiziana Genovese; Nimesh S A Patel; Carmelo Muià; Michael D Threadgill; Angelina De Sarro; Christoph Thiemermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-18       Impact factor: 3.000

4.  Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; H Mota-Filipe; T Centorrino; M L Terranova; A Ciccolo; D Britti; A P Caputi; C Thiemermann
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.

Authors:  M N Muscará; W McKnight; S Asfaha; J L Wallace
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

6.  Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.

Authors:  O Morteau; S G Morham; R Sellon; L A Dieleman; R Langenbach; O Smithies; R B Sartor
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

7.  Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat.

Authors:  T C Peterson; C E Cleary; A M Shaw; D A Malatjalian; S J Veldhuyzen van Zanten
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

8.  Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

Authors:  B K Reuter; S Asfaha; A Buret; K A Sharkey; J L Wallace
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

9.  The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis.

Authors:  A Miranda; E Nordstrom; A Mannem; C Smith; B Banerjee; J N Sengupta
Journal:  Neuroscience       Date:  2007-08-23       Impact factor: 3.590

10.  Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors.

Authors:  Hiroshi Matsumoto; Takahiro Kimura; Kazunori Haga; Noriyuki Kasahara; Peter Anton; Ian McGowan
Journal:  BMC Gastroenterol       Date:  2010-05-11       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.